Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study

Tetsuya Hirata, Gentaro Izumi, Masashi Takamura, Ako Saito, Akari Nakazawa, Miyuki Harada, Yasushi Hirota, Kaori Koga, Tomoyuki Fujii, Yutaka Osuga
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2014 · vol. 30(10) , pp. 726–729 · doi:10.3109/09513590.2014.926882 · PMID:24905725 · W1988101865
article OA: closed CC0 ⤵ 48 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Dienogest significantly reduced pelvic pain and serum CA-125/CA19-9 levels in 15 women with symptomatic adenomyosis over 24 weeks, with metrorrhagia being the most frequent adverse effect.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Adenomyosis is a common disorder in premenopausal women that causes dysmenorrhea, pelvic pain and menorrhagia. Considering that adenomyosis is an estrogen-dependent disease, the medical treatment is based on this hormone. Effective and well-tolerated medical treatments for symptomatic adenomyosis are needed. Dienogest, an oral progestin, has been extensively investigated in the treatment of endometriosis. In this report, we present the results on the efficacy and safety of dienogest in the treatment of symptomatic adenomyosis. Seventeen patients with symptomatic adenomyosis were included in this study, of which 15 continued dienogest for up to 24 weeks. Dienogest significantly reduced adenomyosis-associated pelvic pain as well as serum CA-125 and CA19-9 levels. It also demonstrated a modest suppression of estradiol (>50 pg/ mL), which is consistent with the findings of other reports. During treatment, five patients experienced worsening anemia because of metrorrhagia, which is the most frequent adverse effect associated with dienogest. This report suggests that dienogest is an effective and well-tolerated therapy for symptomatic adenomyosis.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosisdysmenorrhea

MeSH descriptors

Adenomyosis Metrorrhagia Nandrolone Progesterone Congeners Adenomyosis Adult Female Humans Metrorrhagia Middle Aged Nandrolone Nandrolone Nandrolone Nandrolone Pilot Projects Progesterone Congeners Progesterone Congeners Progesterone Congeners Treatment Outcome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (48)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T16:23:13.998983+00:00
pubmed
last seen: 2026-05-13T22:18:29.016410+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK